Evidence map›Paper›PMID 36144667›Full record

ArticleMolecules (Basel, Switzerland)2022

Effective Preparation of [

Mohammad B Haskali, Peter D Roselt, Terence J O'Brien, Craig A Hutton, Idrish Ali, Lucy Vivash, Bianca Jupp

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Radiosynthesis of [18F]-flumazenil Using an Isotopic Approach.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mohammad B HaskaliSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0003-3084-2084
Peter D RoseltThe Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Terence J O'BrienDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
Craig A HuttonSchool of Chemistry, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0002-2353-9258
Idrish AliDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
Lucy VivashDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
Bianca JuppDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.ORCID 0000-0002-9163-9170
Monash University · AUThe University of Melbourne · AUPeter MacCallum Cancer Centre · AU

Funding

National Health and Medical Research Council GNT1176426
6 · The paper itself

Abstract

(1) Background: [18F]Flumazenil 1 ([18F]FMZ) is an established positron emission tomography (PET) radiotracer for the imaging of the gamma-aminobutyric acid (GABA) receptor subtype, GABAA in the brain. The production of [18F]FMZ 1 for its clinical use has proven to be challenging, requiring harsh radiochemical conditions, while affording low radiochemical yields. Fully characterized, new methods for the improved production of [18F]FMZ 1 are needed. (2) Methods: We investigate the use of late-stage copper-mediated radiofluorination of aryl stannanes to improve the production of [18F]FMZ 1 that is suitable for clinical use. Mass spectrometry was used to identify the chemical by-products that were produced under the reaction conditions. (3) Results: The radiosynthesis of [18F]FMZ 1 was fully automated using the iPhase FlexLab radiochemistry module, affording a 22.2 ± 2.7% (n = 5) decay-corrected yield after 80 min. [18F]FMZ 1 was obtained with a high radiochemical purity (>98%) and molar activity (247.9 ± 25.9 GBq/µmol). (4) Conclusions: The copper-mediated radiofluorination of the stannyl precursor is an effective strategy for the production of clinically suitable [18F]FMZ 1.

Indexed as

CopperFlumazenilFluorine Radioisotopesgamma-Aminobutyric AcidPositron-Emission TomographyRadiopharmaceuticalsCopperFlumazenilFluorine Radioisotopesgamma-Aminobutyric AcidRadiopharmaceuticalsbenzodiazepineFlumazenil 1GABAAPET imagingradiochemistryradiofluorinationstannanestannyl

Identifiers

PMID36144667
PMCPMC9505495
OpenAlexW4296018165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.